Delivery Order SPE2DB22D3501-SPE2DB25FXD54
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,635.77 to AmerisourceBergen Drug Corp for the supply of Remifentanil 1 mg vials. This contract, issued on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,193.89 to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Remifentanil is a potent synthetic opioid analgesic commonly used in medical and surgical...
- The Defense Logistics Agency awarded a $2,055.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials, with an ultimate completion date of August 11, 2025. This is a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials under a firm fixed-price contract. This award, issued on August 28, 2025, carries a ceiling value of $10,266.97 and is expected to reach ultimate completion on August 29, 2025. The contract is a non-set-aside, competitively awarded delivery order that leverages AmerisourceBergen's broader relationship with DLA to fulfill critical pharmaceutical needs. Performance will be...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Remifentanil 2 mg vials, with a contract ceiling value of $9,762.12. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and performance location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier supporting federal...
- The Defense Logistics Agency awarded a delivery order valued at $11,983.47 to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials, a potent opioid analgesic commonly used in clinical and surgical settings. This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,522.64 to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials. This is a firm fixed price delivery order, effective through August 25, 2025, and represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Remifentanil is a potent synthetic opioid analgesic commonly used in...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $5,317.05 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 1 mg vials of the pharmaceutical drug remifentanil. The contract has a completion date of February 1, 2024 and was awarded on January 31, 2024. AmerisourceBergen Drug Corp, as the prime contractor, will deliver the pharmaceutical product to support military treatment programs and facilities. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials under a firm fixed-price contract. The award, issued on August 11, 2025, carries a ceiling value of $7,572.90 with an ultimate completion date of August 12, 2025. This delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Remifentanil is a potent synthetic opioid...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $25,489.05 contract is for the delivery of Remifentanil 5 mg vials, with a period of performance ending on June 30, 2025. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXD54Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,426.20 to AmerisourceBergen Drug Corp for the supply of Remifentanil 2 mg vials, with an ultimate completion date of September 4, 2025. This non-set-aside contract employs firm fixed pricing and represents a competitively awarded delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's comprehensive $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which extends through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor and critical federal medical procurement vendor, regularly fulfills federal orders for pharmaceuticals and medical supplies through competitive awards. As a child contract under this larger vehicle, the Remifentanil order exemplifies the company's role in supplying specialized pharmaceutical products to support Department of Defense healthcare operations and military readiness requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/3/25 |